Do analysts recommend VERO or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VERO or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Venus Concept's return on equity of -1,904.25% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% GlucoTrack N/A -2,135.52% -290.22%

Do analysts prefer VERO or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VERO or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, VERO or PFSA?

Profusa has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Venus Concept $58.88M 0.01 -$47M -$48.84 N/A Profusa $100K 11.65 -$35.82M -$5.62 thousand N/A

Is VERO or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Profusa N/A N/A -1,731.09%

Do analysts recommend VERO or AEMD?

Aethlon Medical has a consensus price target of $1.50, indicating a potential downside of 76.23%. Given Aethlon Medical's stronger consensus rating and higher possible upside, analysts plainly believe Aethlon Medical is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend VERO or FEED?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VERO or FEED more profitable?

Venus Concept has a net margin of -92.76% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Nanovibronix -1,093.61% -60.73% -48.48%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 09/18/2026

Compare

VERO vs. GCTK, BBLG, PFSA, AEMD, and FEED

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include GlucoTrack (GCTK), Bone Biologics (BBLG), Profusa (PFSA), Aethlon Medical (AEMD), and Nanovibronix (FEED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to GlucoTrack?

Venus Concept (NASDAQ:VERO) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Venus Concept's return on equity of -1,904.25% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
GlucoTrack	N/A	-2,135.52%	-290.22%

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 5.9% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

GlucoTrack has lower revenue, but higher earnings than Venus Concept. GlucoTrack is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

In the previous week, GlucoTrack had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for GlucoTrack and 0 mentions for Venus Concept. GlucoTrack's average media sentiment score of 0.66 beat Venus Concept's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Venus Concept	Neutral
GlucoTrack	Positive

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

Venus Concept beats GlucoTrack on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Bone Biologics?

Venus Concept (NASDAQ:VERO) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 5.0% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -57.87% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Bone Biologics	N/A	-57.87%	-53.65%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Bone Biologics	Neutral

Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Bone Biologics has lower revenue, but higher earnings than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

Summary

Bone Biologics beats Venus Concept on 6 of the 10 factors compared between the two stocks.

How does Venus Concept compare to Profusa?

Venus Concept (NASDAQ:VERO) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 15.0% of Profusa shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profusa has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Profusa	$100K	11.65	-$35.82M	-$5.62 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Profusa	N/A	N/A	-1,731.09%

In the previous week, Profusa had 6 more articles in the media than Venus Concept. MarketBeat recorded 6 mentions for Profusa and 0 mentions for Venus Concept. Profusa's average media sentiment score of 0.58 beat Venus Concept's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
Venus Concept	Neutral
Profusa	Positive

Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Profusa has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Summary

Profusa beats Venus Concept on 8 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Aethlon Medical?

Venus Concept (NASDAQ:VERO) and Aethlon Medical (NASDAQ:AEMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Aethlon Medical has lower revenue, but higher earnings than Venus Concept. Aethlon Medical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A

Aethlon Medical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Aethlon Medical's return on equity of -123.08% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Aethlon Medical	N/A	-123.08%	-99.28%

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by insiders. Comparatively, 0.6% of Aethlon Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aethlon Medical had 17 more articles in the media than Venus Concept. MarketBeat recorded 17 mentions for Aethlon Medical and 0 mentions for Venus Concept. Aethlon Medical's average media sentiment score of 0.23 beat Venus Concept's score of 0.00 indicating that Aethlon Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Venus Concept	Neutral
Aethlon Medical	Neutral

Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Aethlon Medical has a consensus price target of $1.50, indicating a potential downside of 76.23%. Given Aethlon Medical's stronger consensus rating and higher possible upside, analysts plainly believe Aethlon Medical is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Aethlon Medical beats Venus Concept on 9 of the 14 factors compared between the two stocks.

How does Venus Concept compare to Nanovibronix?

Venus Concept (NASDAQ:VERO) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Venus Concept has a net margin of -92.76% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Nanovibronix	-1,093.61%	-60.73%	-48.48%

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 12.2% of Nanovibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nanovibronix had 5 more articles in the media than Venus Concept. MarketBeat recorded 5 mentions for Nanovibronix and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Nanovibronix	Neutral

Nanovibronix has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Nanovibronix	$1.93M	0.36	-$18.18M	-$117.28	N/A

Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Summary

Nanovibronix beats Venus Concept on 7 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$442K	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-0.01	25.34	275.49	25.40
Price / Sales	0.01	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	0.07	5.69	10.46	6.33
Net Income	-$47M	$151.55M	$3.49B	$358.33M
7 Day Performance	N/A	0.66%	0.59%	1.12%
1 Month Performance	N/A	-3.33%	-1.74%	-2.39%
1 Year Performance	-86.44%	6.79%	18.13%	5.35%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	0.1101 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
GCTK GlucoTrack	1.0883 of 5 stars	$2.30 +1.1%	N/A	-97.5%	$1.63M	N/A	N/A	5	News Coverage Gap Up
BBLG Bone Biologics	1.2785 of 5 stars	$0.55 +2.6%	N/A	-75.5%	$1.53M	N/A	N/A	2	Gap Up
PFSA Profusa	0.8789 of 5 stars	$1.95 +6.8%	N/A	N/A	$1.16M	$100K	N/A	2
AEMD Aethlon Medical	1.0256 of 5 stars	$1.46 -0.6%	$1.50 +2.7%	-82.7%	$1.04M	N/A	N/A	10	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. GCTK, BBLG, PFSA, AEMD, and FEED

How does Venus Concept compare to GlucoTrack?

Summary

How does Venus Concept compare to Bone Biologics?

Summary

How does Venus Concept compare to Profusa?

Summary

How does Venus Concept compare to Aethlon Medical?

Summary

How does Venus Concept compare to Nanovibronix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. GCTK, BBLG, PFSA, AEMD, and FEED

How does Venus Concept compare to GlucoTrack?

Do analysts recommend VERO or GCTK?

Is VERO or GCTK more profitable?

Do insiders and institutionals believe in VERO or GCTK?

Which has better valuation and earnings, VERO or GCTK?

Does the media refer more to VERO or GCTK?

Which has more volatility & risk, VERO or GCTK?

Summary

How does Venus Concept compare to Bone Biologics?

Do institutionals and insiders hold more shares of VERO or BBLG?

Is VERO or BBLG more profitable?

Do analysts prefer VERO or BBLG?

Does the media refer more to VERO or BBLG?

Which has more volatility and risk, VERO or BBLG?

Which has stronger valuation and earnings, VERO or BBLG?

Summary

How does Venus Concept compare to Profusa?

Do insiders and institutionals hold more shares of VERO or PFSA?

Which has higher valuation and earnings, VERO or PFSA?

Do analysts recommend VERO or PFSA?

Is VERO or PFSA more profitable?

Does the media prefer VERO or PFSA?

Which has more volatility and risk, VERO or PFSA?

Summary

How does Venus Concept compare to Aethlon Medical?

Which has preferable earnings & valuation, VERO or AEMD?

Is VERO or AEMD more profitable?

Do insiders & institutionals believe in VERO or AEMD?

Does the media prefer VERO or AEMD?

Which has more risk & volatility, VERO or AEMD?

Do analysts recommend VERO or AEMD?

Summary

How does Venus Concept compare to Nanovibronix?

Do analysts recommend VERO or FEED?

Is VERO or FEED more profitable?

Do institutionals and insiders believe in VERO or FEED?

Does the media refer more to VERO or FEED?

Which has higher earnings and valuation, VERO or FEED?

Which has more volatility & risk, VERO or FEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools